Floatz logo

ONATASERTIB

Advanced Solid Tumor

Shanghai Antengene Corporation LimitedSmall moleculePhase 2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
59/ 100

Competitive context

1412 Active assets in the Advanced Solid Tumor cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

ONATASERTIB is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerDormant
CC
Indicative ·
45 / 100
View asset →
carcinoid tumorDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →